Terremoto Biosciences

Raised $108M in a Series C round, announced 15 April 2026.

Total raised: $108M

Latest round Series CCountry United StatesSector Health

Round

$108MSeries C, 15 April 2026

Funds clinical trials of AKT1 inhibitors in oncology and hereditary hemorrhagic telangiectasia.

Amount: $108M
Stage: Series C
Announced: 15 April 2026
Lead: RA Capital Management
Other investors: Deep Track Capital, Osage University Partners, BeOne Medicines, OrbiMed, Third Rock Ventures, Novo Holdings, Cormorant Asset Management
Use of funds: Funds clinical trials of AKT1 inhibitors in oncology and hereditary hemorrhagic telangiectasia.
Checked: Announced by the company
Sources: Terremoto Biosciences closes $108M Series C cooley.com
Terremoto Biosciences closes $108M Series C pulse2.com

Company

Develops selective small-molecule AKT1 inhibitors for cancer and rare disease

Based in: South San Francisco, United States
Sector: Health
Website: terremotobio.com ↗

Questions

How much has Terremoto Biosciences raised?

Terremoto Biosciences raised $108M in a Series C round, announced on 15 April 2026.

Who invested in Terremoto Biosciences?

RA Capital Management led. Investors include RA Capital Management, Deep Track Capital, Osage University Partners, BeOne Medicines, OrbiMed and Third Rock Ventures.